Apellis Pharmaceuticals, Inc. (APLS) Major Shareholder Global Strategic Fund I. Venbio Buys 127,515 Shares of Stock
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) major shareholder Global Strategic Fund I. Venbio bought 127,515 shares of the business’s stock in a transaction on Monday, November 13th. The shares were acquired at an average price of $14.00 per share, for a total transaction of $1,785,210.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Major shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) opened at $14.10 on Tuesday. Apellis Pharmaceuticals, Inc. has a 52-week low of $13.15 and a 52-week high of $14.90.
About Apellis Pharmaceuticals
Apellis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases. The Company’s lead compounds are designed to inhibit complement component 3 (C3), the central protein in the complement cascade.
Receive News & Ratings for Apellis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apellis Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.